BrainStorm Cell Therapeutics Inc (BCLI)

[early_retirement2]

INVESTOR CALL UPDATE:

http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=RssLanding&cat=news&id=2227741

BrainStorm to Host Year End Call with Investors to Discuss Important Corporate Developments Company Explores Regulatory Commercial Pathways for NurOwn®

Conference Call and Live Webcast on December 19 at 8:30 am Eastern Time


HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 6, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a conference call on December 19 at 8:30 am Eastern Time. Mr. Chaim Lebovits, BrainStorm's President and Chief Executive Officer, will provide an update to shareholders to discuss ongoing progress with NurOwn® in the treatment of amyotropic lateral sclerosis (ALS). Mr. Lebovits will lay out plans for 2017, including a discussion on a planned registration trial as well as a new pathway that may potentially provide patients with access to NurOwn.


The call will be conducted in English. Callers may participate in the conference call by dialing:


USA:

888-389-5987

Canada:

719-325-2425

Israel:

1 80 924 5905

Conference ID:

3566333

Webcast:

http://public.viavid.com/index.php?id=122186